Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: August 18, 2026
Reporting Period: Single event date (August 18, 2026)
Business Overview: The Company is a Delaware corporation listed on the Nasdaq Capital Market. It is designated as an emerging growth company.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain audited or unaudited financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change reported is the execution of a new commercial agreement:
- Event: Entered into a distribution agreement with AvMEDICAL.
- Counterparty Profile: AvMEDICAL is a Service-Disabled Veteran-Owned Small Business (SDVSB) and an established distributor of premium medical and surgical laboratory services, supplies, and equipment to government agencies.
- Strategic Impact: This agreement expands the Company's distribution network, specifically targeting government agency channels.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the agreement but does not include specific forward-looking guidance, revenue projections, or management commentary on future financial performance within the text of the 8-K itself.
Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in this filing beyond the standard nature of entering into new commercial contracts.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific terms of the AvMEDICAL distribution agreement, including duration, exclusivity, and financial obligations.
- Verify the financial health and market standing of AvMEDICAL as a distributor for government agencies.
- Monitor subsequent filings (10-Q or 10-K) to assess the revenue impact of this new distribution channel.
- Confirm the Company's continued status as an emerging growth company and any implications for financial reporting standards.